On Tuesday, Shares of AK Steel Holding Corporation (NYSE:AKS), gained 0.90% to $5.58.
On May 1, AK Steel Coshocton (Ohio) Works has been recognized for outstanding safety performance by the Ohio Bureau of Workers’ Compensation, Division of Safety and Hygiene. The recognition is part of a collaborative safety awareness program established by the Coshocton County Safety Council and Chamber of Commerce.
AK Steel’s Coshocton Works received the “Special Award for Safety” for operating 2,245,862 hours without a lost-time injury between August 5, 2011 and April 23, 2014. AK Steel’s corporate-wide safety performance led the steel industry by a wide margin for the full-year 2014.
AK Steel Holding Corporation, through its partner, AK Steel Corporation, produces flat-rolled carbon, stainless and electrical steel, and tubular products in the United States and internationally. It produces flat-rolled value-added carbon steels, counting coated, cold-rolled, and hot-rolled carbon steel products; and specialty stainless and electrical steels in sheet and strip forms.
Shares of Archer-Daniels-Midland Company (NYSE:ADM), inclined 0.62% to $51.92, during its last trading session.
Archer-Daniels-Midland Company, declared at its 92nd Annual Stockholders’ Meeting that 13 incumbent directors were elected to its Board. The directors are: Alan L. Boeckmann, Mollie Hale Carter, Terrell K. Crews, Pierre Dufour, Donald E. Felsinger, Juan R. Luciano, Antonio Maciel Neto, Patrick J. Moore, Thomas F. O’Neill, Francisco Sanchez, Daniel Shih, Kelvin R. Westbrook and Patricia A. Woertz.
ADM’s Board of Directors also declared a cash dividend of 28.0 cents per share on the company’s common stock payable June 11, 2015, to Stockholders of record May 21, 2015.
This is ADM’s 334th successive quarterly payment, a record of 83 years of uninterrupted dividends. As of March 31, 2015, there were 625,071,516 shares of ADM common stock outstanding.
Archer-Daniels-Midland Company procures, transports, stores, processes, and merchandises agricultural commodities and products. The company’s Oilseeds Processing segment originates, merchandises, crushes, and processes soybeans and soft seeds into vegetable oils and protein meals.
At the end of Tuesday’s trade, Shares of McDonald’s Corp. (NYSE:MCD), gained 0.45% to $97.95.
On May 4, McDonald’s President and Chief Executive Officer Steve Easterbrook declared the initial steps of the Company’s turnaround plan counting a restructuring of McDonald’s worldwide business and financial updates.
Starting July 1, 2015, McDonald’s will operate under a new organizational structure with the following market segments:
- S. - the Company’s largest segment, accounting for more than 40% of the Company’s 2014 operating income;
- International Lead Markets - established markets counting Australia, Canada, France, Germany and the U.K., which operate within similar economic and competitive dynamics, offer similar growth opportunities and collectively represented about 40% of the Company’s 2014 operating income;
- High-Growth Markets - markets with relatively higher restaurant expansion and franchising potential counting China, Italy, Poland, Russia, South Korea, Spain, Switzerland and the Netherlands. Together these markets accounted for about 10% of the Company’s 2014 operating income; and
- Foundational Markets - the remaining markets in the McDonald’s system, each of which has the potential to operate under a largely franchised model. Corporate activities will also be stated within this segment.
McDonald’s Corporation operates and franchises McDonald’s restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, and Latin America. The company’s restaurants offer various food products, soft drinks, coffee, and other beverages.
Finally, Celgene Corporation (NASDAQ:CELG), ended its last trade with 0.16% gain, and closed at $113.58.
On April 27, Celgene Corporation and Quanticel Pharmaceuticals, Inc., declared a definitive share purchase agreement under which Celgene Corporation will acquire Quanticel. Through the agreement, Celgene will have full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, in addition to Quanticel’s lead programs that target specific epigenetic modifiers to advance Celgene’s pipeline of innovative cancer therapies.
The acquisition culminates a 2011 planned alliance between Celgene and Quanticel. Over the course of the three-and-a-half year alliance, Quanticel industrialized its single-cell platform for analysis of tumor cellular content and applied it to novel target discovery and the generation of high-quality drug candidates. Multiple drug candidates from Quanticel are predictable to enter the clinic in early 2016.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
